Chemomab Therapeutics CMMB
NASDAQ CMMB
$1.18 +0.00 (+0.00%)
As of: Oct 21, 2026 · 10:28 AM EDT

Chemomab Therapeutics (CMMB) Convertible Debt (2011 - 2012)

Updated

Analysis

Chemomab Therapeutics (CMMB) Convertible Debt (2011 - 2012) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,131.65 Bn 1,100.24 Bn 19.71 Bn
2 Johnson & Johnson 615.89 Bn 534.41 Bn 17.26 Bn
3 AbbVie 505.03 Bn 478.14 Bn 12.70 Bn
4 Merck 368.78 Bn 323.16 Bn 12.21 Bn
5 Novartis Ag 298.66 Bn 262.65 Bn 11.24 Bn
6 Astrazeneca 262.09 Bn 235.78 Bn 12.86 Bn
7 Amgen 236.57 Bn 191.97 Bn 7.24 Bn
8 Gilead Sciences 191.05 Bn 165.25 Bn 6.22 Bn
9 Pfizer 170.60 Bn 117.25 Bn 10.94 Bn
10 Chemomab Therapeutics 7.53 Mn -27.63 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2012 2.48 Mn
Jun 30, 2012 3.39 Mn
Dec 31, 2011 2.43 Mn
Sep 30, 2011 2.52 Mn
Jun 30, 2011 2.95 Mn
API Access

Chemomab Therapeutics Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=CMMB&period=max&api_key=YOUR_API_KEY